Update on therapeutic developments for hereditary angioedema

Allergy and Asthma Proceedings

Volumn 30, Issue 5, 2009, Pages 500-505

  Christiansen, Sandra C ^a   Zuraw, Bruce L ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Angioedema; Antifibrinolytics; Attenuated androgens; Bradykinin; Bradykinin B2 receptor; C1 inhibitor; Ecallantide; Icatibant; Prophylaxis

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; ICATIBANT; KALBITOR; PLASMA KALLIKREIN; RECOMBINANT COMPLEMENT COMPONENT C1S INHIBITOR; RHUCIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ALLERGIC REACTION; ANGIONEUROTIC EDEMA; BLOOD VESSEL PERMEABILITY; CASE REPORT; CONFERENCE PAPER; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; HUMAN; INFECTION; LONG TERM CARE; PROPHYLAXIS; QUALITY OF LIFE; SHORT COURSE THERAPY; STATISTICAL SIGNIFICANCE; UNITED STATES;

ANGIOEDEMAS, HEREDITARY; BRADYKININ; CAPILLARY PERMEABILITY; CLINICAL TRIALS AS TOPIC; COMPLEMENT C1 INHIBITOR PROTEIN; ENZYME REPLACEMENT THERAPY; HUMANS; PLASMA KALLIKREIN; RECEPTORS, BRADYKININ; RECOMBINANT PROTEINS;

EID: 73249123246     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3282     Document Type: Conference Paper

References (44)

1. Nilsson IM, Andersson L, and Bjorkman SE. Epsilon-aminocaproic acid (E-ACA) as a therapeutic agent based on 5 year's clinical experience. Acta Med Scand Suppl 448:1-46, 1966.
2. Spaulding WB. Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema). Ann Intern Med 53:739-745, 1960.
3. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 359:1027-1036, 2008.
4. Zuraw BL, and Christiansen SC. New promise and hope for treating hereditary angioedema. Expert Opin Investig Drugs 17:697-706, 2008.
5. Donaldson VH, and Evans RR. A biochemical abnormality in hereditary angioneurotic edema: Absence of serum inhibitor of C′1-esterase. Am J Med 35:37-44, 1963.
6. Sheffer AL, Fearon DT, and Austen KF. Hereditary angioedema: A decade of management with stanozolol. J Allergy Clin Immunol 80:855-860, 1987.
7. Pickering RJ, Good RA, Kelly JR, and Gewurz H. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet 1:326-330, 1969.
8. Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 98:383-388, 2007.
9. Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109:1057-1063, 2002.
10. Davis AE, III. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 6:595-628, 1988.
11. Lomas DA, Belorgey D, Mallya M, et al. Molecular mousetraps and the serpinopathies. Biochem Soc Trans 33:321-330, 2005.
12. Agostoni A, Bergamaschini L, Martignoni G, et al. Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann Allergy 44:299-301, 1980.
13. Gadek JE, Hosea SW, Gelfand JA, et al. Replacement therapy in hereditary angioedema. Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med 302:542-546, 1980.
14. Marasini B, Cicardi M, Martignoni GC, and Agostoni A. Treatment of hereditary angioedema. Klin Wochenschr 56:819-823, 1978.
15. Bergamaschini L, Cicardi M, Tucci A, et al. C1 INH concentrate in the therapy of hereditary angioedema. Allergy 38:81-84, 1983.
16. Bork K, and Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 161:714-718, 2001.
17. Kirschfink M, and Mollnes TE. C1-inhibitor: An anti-inflammatory reagent with therapeutic potential. Expert Opin Pharmacother 2:1073-1083, 2001.
18. Logan RA, and Greaves MW. Hereditary angio-oedema: Treatment with C1 esterase inhibitor concentrate. J R Soc Med 77: 1046-1048, 1984.
19. Agostoni A, and Cicardi M. Hereditary and acquired C1-inhibitor deficiency: Biological and clinical characteristics in 235 patients. Medicine (Baltimore) 71:206-215, 1992.
20. Bork K, Hardt J, Schicketanz KH, and Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 163:1229-1235, 2003.
21. Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 38: 540-549, 1998.
22. De Serres J, Groner A, and Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: A review. Transfus Apheresis Sci 29:247-254, 2003.
23. Bork K, and Witzke G. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 83:677-682, 1989.
24. Altman AD, McLaughlin J, Schellenberg R, et al. Hereditary angioedema managed with low-dose danazol and c1 esterase inhibitor concentrate: A case report. J Obstet Gynaecol Can 28:27-31, 2006.
25. Lehmann A, Lang J, Boldt J, and Saggau W. Successful offpump coronary artery bypass graft surgery in a patient with hereditary angioedema. J Cardiothorac Vasc Anesth 16:473-476, 2002.
26. Leimgruber A, Jaques WA, and Spaeth PJ. Hereditary angioedema: Uncomplicated maxillofacial surgery using short-term C1 inhibitor replacement therapy. Int Arch Allergy Immunol 101:107-112, 1993.
27. Maves KK, and Weiler JM. Tonsillectomy in a patient with hereditary angioedema after prophylaxis with C1 inhibitor concentrate. Ann Allergy 73:435-438, 1994.
28. Mohr M, Pollok-Kopp B, Gotze O, and Burchardi H. The use of a C1-inhibior concentrate for short-term preoperative prophylaxis in two patients with hereditary angioedema. Anaesthesist 45:626-630, 1996.
29. Cicardi M, and Zingale L. How do we treat patients with hereditary angioedema. Transfus Apher Sci 29:221-227, 2003.
30. Bergamaschini L, and Cicardi M. Recent advances in the use of C1 inhibitor as a therapeutic agent. Mol Immunol 40:155-158, 2003.
31. Waytes AT, Rosen FS, and Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 334:1630-1634, 1996.
32. Zuraw BL, Busse P, White M, et al. Efficacy and safety of long term prophylaxis with C1 inhibitor (C1inh) concentrate in patients with hereditary angioedema (HAE). J Allergy Clin Immunol 121:S231, 2008.
33. Pharming Group NV. Press Release, July 1, 2009. Available online at www.pharming.com; last accessed 2008.
34. Juhlin L, and Michaelsson G. Use of a kallikrein inhibitor in the treatment of urticaria and hereditary angioneurotic edema. Acta Derm Venereol 49:37-44, 1969.
35. Bauer J, Futterman S, and Dreiling DA. Anaphylactic shock secondary to initial Trasylol administration. Am J Gastroenterol 56:542-544, 1971.
36. Proud G, and Chamberlain J. Letter: Anaphylactic reaction to aprotinin. Lancet 2:48-49, 1976.
37. Williams A, and Baird LG. DX-88 and HAE: A developmental perspective. Transfus Apheresis Sci 29:255-258, 2003.
38. Levy R, McNeil D, Li H, et al. Results of a 2-stage, phase 3 pivotal trial EDEMA3: A study of subcutaneous DX-88 (Ecallantide), a plasma kallikrein Inhibitor, in patients with hereditary angioedema (HAE). J Allergy Clin Immunol 121:S231, 2008.
39. US National Institutes of Health. Clinical trials. Available online at www.clinicaltrials.gov; last accessed August 2009.
40. Caballero T, and Lopez-Serrano C. Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J Allergy Clin Immunol 117:476-477, 2006.
41. Beck TR, and Baird LG. Reply: Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J Allergy Clin Immunol 117:477, 2006.
42. Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: In vitro studies. Br J Pharmacol 102:769-773, 1991.
43. Bork K, Yasothan U, and Kirkpatrick P. Icatibant. Nat Rev Drug Discov 7:801-802, 2008.
44. Levi M, Choi G, Picavet C, and Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 117:904-908, 2006.